🔥 HS Comorbidity Screening (Metabolic Syndrome) Simulator

Shared Inflammatory Pathway Linking HS and Metabolic Syndrome

A common cytokine axis drives both diseases together.

• TNF-α / IL-17: Key cytokines (shared HS-MetS drivers)
• ~40%: MetS in HS cohorts (reported prevalence estimate)
• Common: CRP elevation (systemic inflammation marker)
• Bidirectional: Onset pattern (each may worsen the other)

Cytokine overlap between HS and metabolic disease

Placeholder: TNF-α and IL-17 link follicular inflammation to insulin resistance.

Placeholder: shared inflammation supports routine metabolic screening in HS.

Waist Circumference and Obesity as an HS Risk Amplifier

Central obesity worsens follicular occlusion and disease severity.

• ~50-70%: Obesity prevalence in HS (higher than general population)
• >88 cm: Waist cutoff (women) (ATP III criterion)
• >102 cm: Waist cutoff (men) (ATP III criterion)
• Improves HS: Weight loss effect (reduces flare frequency)

Mechanical and hormonal effects of central adiposity

Placeholder: adipose tissue adds mechanical friction and adipokine-driven inflammation.

Placeholder: waist measurement should be routine at every HS visit.

Insulin Resistance and Type 2 Diabetes Risk in HS

Chronic inflammation drives measurable insulin resistance in HS.

• ~2x: T2D risk increase (versus matched controls)
• >100 mg/dL: Fasting glucose cutoff (MetS criterion)
• Frequent: HOMA-IR elevation (even without diabetes diagnosis)
• Annual: Screening interval (suggested fasting glucose check)

Why insulin resistance tracks with HS severity

Placeholder: worsening Hurley stage correlates with rising insulin resistance markers.

Placeholder: consider HbA1c testing alongside dermatologic HS evaluation.

Hypertension and Dyslipidemia Screening in HS Patients

Blood pressure and lipid panels are frequently overlooked in HS.

• ≥130/85: BP cutoff (MetS criterion threshold)
• <40/50 mg/dL: Low HDL cutoff (men/women threshold)
• ≥150 mg/dL: Triglyceride cutoff (MetS criterion)
• Elevated: Cardiovascular risk (in moderate-severe HS)

Integrating cardiometabolic panels into HS follow-up

Placeholder: routine BP and lipid checks catch silent cardiometabolic risk.

Placeholder: pair dermatology visits with periodic cardiometabolic screening.

Combined Comorbidity Management for HS and Metabolic Syndrome

Coordinated multidisciplinary care improves both conditions together.

• Derm + Endo + PCP: Recommended team (multidisciplinary model)
• First-line: Lifestyle intervention (diet, activity, weight management)
• Anti-TNF/IL-17: Biologic therapy overlap (may benefit both conditions)
• Every 3-6 mo: Follow-up cadence (suggested joint review)

Building an integrated HS-metabolic care pathway

Placeholder: shared care pathways reduce fragmented, delayed comorbidity treatment.

Placeholder: screen every HS patient for metabolic syndrome at diagnosis.